PTJ
PRTK

Paul Tudor Jones’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Paul Tudor Jones’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-62,500
Closed -$869K – 1801
2016
Q2 		$869K Buy
+62,500
New +$920K 0.02% 512

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Paul Tudor Jones's PRTK Position: Q3 2016 in Review

Paul Tudor Jones sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 62,500 shares — an estimated $869K sold.

Paul Tudor Jones first reported a position in PRTK in Q2 2016 and held it in 1 quarter. The position peaked at $869K in Q2 2016. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

  • Paul Tudor Jones reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Paul Tudor Jones sold 62,500 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $869K.
  • Paul Tudor Jones first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Paul Tudor Jones's Paratek Pharmaceuticals, Inc. position peaked at $869K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on Tudor Investment Corp's 13F filing for Q3 2016, filed 14 Nov 2016.